Azulfidine EN-Tabs (Sulfasalazine Delayed Release Tablets) Drug Information: Medication Guide and Patient Information

Pill Identifier Search

May 25, 2012

Azulfidine

Crohn's Disease »

What is Crohn's disease?

Crohn's disease (also spelled Crohn disease) is a chronic inflammatory disease of the intestines. It primarily causes ulcerations (breaks in the lining) of the small and large intestines, but can affect the digestive system anywhere from the mouth to the anus. It is named after the physician who described the disease in 1932. It also is called granulomatous enteritis or colitis, regional enteritis, ileitis, or terminal ileitis.

Crohn's disease is related closely to another chronic inflammatory condition that involves only the colon called ulcerative colitis. Together, Crohn's disease and ulcerative colitis are frequently referred to as inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease have no medical cure. Once the diseases begin, they tend to fluctuate between periods of inactivity (remission) and activity (relapse).

Inflammatory bowel disease affects approximately 500,000 to two million peop...

Read the Crohn's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Azulfidine EN-Tabs User Reviews >>

Azulfidine EN-Tabs

Ulcerative Colitis Slideshow Pictures

Inflammatory Bowel Disease Slideshow

Digestive Disease Myths Slideshow

font size

PATIENT INFORMATION

Patients should be informed of the possibility of adverse effects and of the need for careful medical supervision. The occurrence of sore throat, fever, pallor, purpura or jaundice may indicate a serious blood disorder. Should any of these occur, the patient should seek medical advice.

Patients should be instructed to take AZULFIDINE EN-tabs (sulfasalazine delayed release tablets) in evenly divided doses, preferably after meals, and to swallow the tablets whole. Additionally, patients should be advised that sulfasalazine may produce an orange-yellow discoloration of the urine or skin.

Ulcerative Colitis

Patients with ulcerative colitis should be made aware that ulcerative colitis rarely remits completely, and that the risk of relapse can be substantially reduced by continued administration of AZULFIDINE EN-tabs (sulfasalazine delayed release tablets) at a maintenance dosage.

Rheumatoid Arthritis

Rheumatoid arthritis rarely remits. Therefore, continued administration of AZULFIDINE EN-tabs is indicated. Patients requiring sulfasalazine should follow up with their physicians to determine the need for continued administration.

Last reviewed on RxList: 10/30/2009
This monograph has been modified to include the generic and brand name in many instances.